Testicular cancer treated in a minor general oncology department.
The question of where to treat testicular cancer and by whom has been debated in several medical journals over the last few year. Here we present data from 98 patients (47 seminomas, 51 non-seminomas) treated between January 1985 and March 1993 at the Department of Oncology, University Hospital of Tromsø, Norway. During a 4-year median follow-up period 2 patients died of progressive disease. Our results are similar to those of major specialised oncology centres. We argue that within the context of multicentre cooperative studies or treatment protocols, patients with testicular cancer can be treated in a small general oncology centre with the same expectations of cure and treatment-related mortality and morbidity as achieved in major centres.
Norum
J
J
Department of Oncology, University Hospital of Tromsø, Norway.
Nordøy
T
T
Wist
E
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D006063:Chorionic Gonadotropin / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009664:Norway; D016522:Oncology Service, Hospital; D012074:Remission Induction; D018239:Seminoma / Q000473:pathology / Q000628:therapy; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D000509:alpha-Fetoproteins / Q000032:analysis
D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D007770:L-Lactate Dehydrogenase